Company news
Maat Pharma (EURONEXT:MAAT) news
Maat Pharma news releases on 6ix. Latest, Sep 29, 2026: MaaT Pharma Publishes its Half-Year 2026 Results and Provides a Business Update
Press releases & updates
MaaT Pharma Publishes its Half-Year 2026 Results and Provides a Business Update
September 29, 2026
MaaT Pharma publie ses résultats semestriels 2026 et fait le point sur ses activités
September 28, 2026
MaaT Pharma Announces Upcoming Pre-IND Meeting with the FDA and Advances MaaT034 Toward Clinical Development in Solid Tumors
September 21, 2026
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination
September 18, 2026
MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 (Xervyteg®) Following Re-Examination for its Conditional Marketing Authorization Application in Europe
September 15, 2026
MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract
July 6, 2026
MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease
June 29, 2026
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026
May 26, 2026
MaaT Pharma Announces Provides an Update on the Application for Marketing Authorization of MaaT013 in the treatment of acute Graft-versus-Host Disease
May 21, 2026
MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease
May 20, 2026
MaaT Pharma to Hold Annual General Meeting on June 16, 2026
May 11, 2026
MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal
April 1, 2026
MaaT Pharma Announces 2025 Annual Results and Provides Business Updates
March 31, 2026
MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation
March 23, 2026
MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management
March 9, 2026
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
February 3, 2026
MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis
January 20, 2026
MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival
December 8, 2025
MaaT Pharma Announces the Successful Completion of Its Global Offering of €9.1 Million
November 14, 2025
MaaT Pharma Launches a Capital Increase of Approximately €9 Million
November 13, 2025
MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034
November 5, 2025
MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update
November 4, 2025
MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease Selected for Oral Presentation at ASH Congress 2025
November 3, 2025
MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
October 7, 2025
MaaT Pharma Publishes Its Half Year 2025 Results and Provides a Business Update
September 17, 2025
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
July 28, 2025
MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux
July 24, 2025
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg(R) in acute Graft-versus Host Disease in Europe
July 3, 2025
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe
July 2, 2025
MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting
June 24, 2025
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
June 19, 2025
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease
June 13, 2025
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease
June 2, 2025
MaaT Pharma to Hold Annual General Meeting on June 20, 2025
May 14, 2025
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025
May 13, 2025
MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
May 12, 2025